A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
Standard
A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. / Meyer, Stefanie; Fuchs, Thomas J; Bosserhoff, Anja K; Hofstädter, Ferdinand; Pauer, Armin; Roth, Volker; Buhmann, Joachim M; Moll, Ingrid; Anagnostou, Nikos; Brandner, Johanna; Ikenberg, Kristian; Moch, Holger; Landthaler, Michael; Vogt, Thomas; Wild, Peter J.
In: PLOS ONE, Vol. 7, No. 6, 6, 2012, p. 38222.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
AU - Meyer, Stefanie
AU - Fuchs, Thomas J
AU - Bosserhoff, Anja K
AU - Hofstädter, Ferdinand
AU - Pauer, Armin
AU - Roth, Volker
AU - Buhmann, Joachim M
AU - Moll, Ingrid
AU - Anagnostou, Nikos
AU - Brandner, Johanna
AU - Ikenberg, Kristian
AU - Moch, Holger
AU - Landthaler, Michael
AU - Vogt, Thomas
AU - Wild, Peter J
PY - 2012
Y1 - 2012
N2 - Current staging methods such as tumor thickness, ulceration and invasion of the sentinel node are known to be prognostic parameters in patients with malignant melanoma (MM). However, predictive molecular marker profiles for risk stratification and therapy optimization are not yet available for routine clinical assessment.
AB - Current staging methods such as tumor thickness, ulceration and invasion of the sentinel node are known to be prognostic parameters in patients with malignant melanoma (MM). However, predictive molecular marker profiles for risk stratification and therapy optimization are not yet available for routine clinical assessment.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Treatment Outcome
KW - Cohort Studies
KW - Prognosis
KW - Proportional Hazards Models
KW - Cells, Cultured
KW - Cell Line, Tumor
KW - Kaplan-Meier Estimate
KW - Tumor Markers, Biological/metabolism
KW - Antigens, CD20/metabolism
KW - Cyclooxygenase 2/metabolism
KW - Immunohistochemistry/statistics & numerical data
KW - Melanoma/metabolism/pathology/therapy
KW - PTEN Phosphohydrolase/metabolism
KW - Purine-Nucleoside Phosphorylase/metabolism
KW - Skin Neoplasms/metabolism/pathology/therapy
KW - Tissue Array Analysis/methods
KW - bcl-2-Associated X Protein/metabolism
KW - bcl-X Protein/metabolism
KW - beta Catenin/metabolism
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Treatment Outcome
KW - Cohort Studies
KW - Prognosis
KW - Proportional Hazards Models
KW - Cells, Cultured
KW - Cell Line, Tumor
KW - Kaplan-Meier Estimate
KW - Tumor Markers, Biological/metabolism
KW - Antigens, CD20/metabolism
KW - Cyclooxygenase 2/metabolism
KW - Immunohistochemistry/statistics & numerical data
KW - Melanoma/metabolism/pathology/therapy
KW - PTEN Phosphohydrolase/metabolism
KW - Purine-Nucleoside Phosphorylase/metabolism
KW - Skin Neoplasms/metabolism/pathology/therapy
KW - Tissue Array Analysis/methods
KW - bcl-2-Associated X Protein/metabolism
KW - bcl-X Protein/metabolism
KW - beta Catenin/metabolism
U2 - 10.1371/journal.pone.0038222
DO - 10.1371/journal.pone.0038222
M3 - SCORING: Journal article
VL - 7
SP - 38222
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 6
M1 - 6
ER -